This product is sold for research purposes only. It is not intended for human consumption, nor is it intended to diagnose, treat, cure, or prevent any disease.
Reconstitute with bacteriostatic (BAC) water for laboratory research preparation.
Overview
GLP‑3 (Glucagon‑Like Peptide‑3) is a synthetic incretin‑related peptide analog
supplied in lyophilised form for laboratory research use only. Preclinical literature
examines its association with enteroendocrine signalling pathways and GPCR‑linked
receptor interaction models under defined experimental conditions.
Research Context
– Investigated in in vitro model systems assessing incretin‑related receptor binding
profiles and downstream cAMP signalling marker readouts.
– Examined in assay configurations referencing enteroendocrine pathway markers and
gut‑hormone signalling cascades under controlled conditions.
– Findings are model‑specific and limited to defined experimental settings.
Format and Documentation
– Lyophilised peptide; nominal content: 5 mg per vial
– Certificate of Analysis (COA) provided for each lot
– Storage guidance for research environments on label/COA
Compliance
For laboratory research use only (RUO). Not for human or veterinary use, diagnostic
or therapeutic applications.
FAQ
What is GLP‑3 in research contexts?
A synthetic incretin‑related peptide analog examined in controlled models for GPCR
receptor binding and enteroendocrine signalling marker readouts.
Do you provide a COA?
Yes — each lot is supplied with a Certificate of Analysis.
How should it be stored in a lab?
Follow the label/COA storage guidance suitable for research environments.
Form: Lyophilised powder
Intended use: Laboratory research use only
Documentation: Certificate of Analysis where applicable
Dispatch: Fast UK fulfilment
Storage:
– Powder: -20°C 3 years ; 4°C 2 years ; 15°C 3 month
– In solvent: -80°C 6 months ; -2°C 1 month ; 10°C 1 week
Product disclaimer
This product is supplied strictly for laboratory research use only. Not for human or veterinary
Reviews
There are no reviews yet.